Molecular pathological changes in the duodenal mucosa in patients with diabetes or functional dyspepsia
- Conditions
- Diabetes Functional dyspepsia
- Registration Number
- JPRN-UMIN000028974
- Lead Sponsor
- Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Not provided
1) Patients with malignant diseases, gastrointestinal-organic diseases (malignancies, peptic ulcers, esophagitis, etc.) or systemic diseases (neurological disease such as Parkinson disease or metabolic diseases except for diabetes). 2) Patients with a history of surgery of the upper gastrointestinal tract (stomach and esophagus). 3) Patients with severe liver dysfunction and renal dysfunction. 4) Patients with mental disorder. 5) A pregnant woman, nursing mother or the subjects who hope pregnancy during this study term. 6) Patients whom doctors judged unsuitable as objects for this study. 7) Patients with H. pylori eradication within 6 months. 8) Patients having the following medicines: prokinetic drugs, H2 blocker, proton pump inhibitor, gastric-mucosal protectant, prostaglandin, NSAIDs, anti-depressants, anti-anxiety agents, sleep inducer, anti-psychotics drugs. However, the patients, who can discontinue those medicines for two or more weeks before study start, can participate in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the expression of inflammatory markers and G protein-coupled receptors among diabetes, functional dyspepsia and control subjects
- Secondary Outcome Measures
Name Time Method